Drug Type Chemical drugs |
Synonyms ACE 34237307, ACE34237307 |
Action inhibitors, antagonists |
Mechanism EGFR C797S inhibitors(Epidermal Growth Factor Receptor C797S inhibitors), EGFR L861Q mutation antagonists, EGFR exon 19 deletion inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Neoplasms | Preclinical | United States | 22 Mar 2024 |